EP Patent

EP4253418A1 — Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof

Assigned to Institucio Catalana de Recerca i Estudis Avancats ICREA · Expires 2023-10-04 · 3y expired

What this patent protects

The present invention relates to immune cells expressing chimeric antigen receptors against p95HER2 and bispecific antibodies for HER2 and CD3 and uses thereof in the treatment of cancer, in particular cancers which overexpress p95HER2.

USPTO Abstract

The present invention relates to immune cells expressing chimeric antigen receptors against p95HER2 and bispecific antibodies for HER2 and CD3 and uses thereof in the treatment of cancer, in particular cancers which overexpress p95HER2.

Drugs covered by this patent

Patent Metadata

Patent number
EP4253418A1
Jurisdiction
EP
Classification
—
Expires
2023-10-04
Drug substance claim
No
Drug product claim
No
Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.